Holen Sie sich die Stockscreener-App
83.93
5.12%
4.09
Schlusskurs vom Vortag:
$79.84
Offen:
$79.99
24-Stunden-Volumen:
353.99K
Relative Volume:
1.03
Marktkapitalisierung:
$1.22B
Einnahmen:
$1.80M
Nettoeinkommen (Verlust:
$1.76B
KGV:
0.7072
EPS:
118.674
Netto-Cashflow:
$-149.23M
1W Leistung:
+6.07%
1M Leistung:
+123.69%
6M Leistung:
+537.77%
1J Leistung:
+500.36%
1-Tages-Spanne:
$79.05
$84.88
1-Wochen-Bereich:
$76.01
$85.75
52-Wochen-Spanne:
$10.80
$86.64
Inhibrx Biosciences Inc Stock (INBX) Company Profile
Firmenname
Inhibrx Biosciences Inc
Sektor
Branche
Telefon
(858) 795-4220
Adresse
11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA
Vergleichen Sie INBX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INBX
Inhibrx Biosciences Inc
|
83.93 | 1.16B | 1.80M | 1.76B | -149.23M | 118.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Inhibrx Biosciences Inc Stock (INBX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-07-23 | Eingeleitet | JMP Securities | Mkt Perform |
| 2024-01-23 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-03-16 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-09-21 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-09-14 | Eingeleitet | Credit Suisse | Outperform |
| 2020-09-14 | Eingeleitet | Evercore ISI | Outperform |
Alle ansehen
Inhibrx Biosciences Inc Aktie (INBX) Neueste Nachrichten
Discipline and Rules-Based Execution in INBX Response - news.stocktradersdaily.com
Will Inhibrx Biosciences Inc. stock deliver shareholder value2025 Key Highlights & Free Real-Time Volume Trigger Notifications - newser.com
What high frequency data says about Inhibrx Biosciences Inc.2025 Market Sentiment & Risk Adjusted Buy and Sell Alerts - newser.com
How high can Inhibrx Biosciences Inc. stock go2025 Valuation Update & Risk Controlled Stock Pick Alerts - newser.com
Multi factor analysis applied to Inhibrx Biosciences Inc.Weekly Gains Report & Weekly Watchlist for Hot Stocks - newser.com
Inhibrx Biosciences Inc. stock daily chart insights2025 Technical Patterns & Free Community Supported Trade Ideas - newser.com
How to recover losses in Inhibrx Biosciences Inc. stock2025 Market Outlook & Safe Capital Growth Tips - newser.com
Inhibrx Biosciences stock rating maintained at Market Perform by Citizens - Investing.com South Africa
Is Inhibrx Biosciences Inc. stock a buy in volatile marketsWeekly Trend Recap & Verified Stock Trade Ideas - newser.com
Will Inhibrx Biosciences Inc. stock pay special dividendsJuly 2025 Recap & Fast Gain Swing Alerts - newser.com
Inhibrx Biosciences Inc (INBX) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - Setenews
Why Inhibrx Biosciences Inc. stock appeals to analystsJuly 2025 Price Swings & Daily Chart Pattern Signal Reports - newser.com
What Wall Street predicts for Inhibrx Biosciences Inc. stock priceQuarterly Trade Summary & Weekly Top Gainers Trade List - newser.com
Press Release: Inhibrx Reports Third Quarter 2025 Financial Results - 富途牛牛
Inhibrx Misses Estimates Even As New Cancer Drug Shows Promise - Finimize
Inhibrx Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
Earnings Flash (INBX) Inhibrx Biosciences Posts Q3 Loss $2.28 a Share - MarketScreener
Inhibrx Biosciences' Q3 net loss widens, misses EPS estimates - MarketScreener
Inhibrx Biosciences, Inc. SEC 10-Q Report - TradingView
[8-K] Inhibrx Biosciences, Inc. Reports Material Event | INBX SEC FilingForm 8-K - Stock Titan
[10-Q] Inhibrx Biosciences, Inc. Quarterly Earnings Report | INBX SEC FilingForm 10-Q - Stock Titan
Inhibrx’s Phase 2 Study on INBRX-109: A Potential Breakthrough in Chondrosarcoma Treatment - MSN
Inhibrx supports CTOS2025 spotlight on chondrosarcoma - Traders Union
Behavioral Patterns of INBX and Institutional Flows - news.stocktradersdaily.com
What does recent volatility data suggest for Inhibrx Biosciences Inc.Quarterly Profit Review & Consistent Income Trade Ideas - newser.com
Is Inhibrx Biosciences Inc. stock resilient to inflationEarnings Overview Summary & Accurate Intraday Trading Signals - newser.com
Tick level data insight on Inhibrx Biosciences Inc. volatilityJuly 2025 Recap & AI Enhanced Trading Alerts - newser.com
Will Inhibrx Biosciences Inc. stock benefit from sector rotation2025 AllTime Highs & Free Daily Entry Point Trade Alerts - newser.com
Finanzdaten der Inhibrx Biosciences Inc-Aktie (INBX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.38%
1.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):